Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 22 (PPIAP22)
- Target
- PPIAP22
- Molecular classification
- Long non-coding RNA (lncRNA), Pseudogene
01
Overview
Peptidylprolyl isomerase A pseudogene 22 (PPIAP22) is a processed pseudogene transcribed as a long non-coding RNA. It is highly homologous to the protein-coding gene peptidylprolyl isomerase A (PPIA; also known as cyclophilin A), but does not encode a protein. PPIAP22 acts as a competing endogenous RNA (ceRNA), primarily sponging microRNA miR-197-3p, thus relieving its inhibitory effect on PPIA mRNA and promoting PPIA protein expression. Elevated levels of PPIAP22 have been identified in hepatocellular carcinoma and other cancers, where its upregulation correlates with poor patient prognosis. Mechanistically, PPIAP22 participates in the regulation of tumor proliferation, immune microenvironment modulation, and possibly mRNA metabolic processes; however, it is not a direct therapeutic target or receptor[1][2][3][4][5][7].
- Other names
- PPIA3LPPIAL3
02
Biological functions
Regulation of gene expression (notably, modulates expression of its parental gene, PPIA, through a competing endogenous RNA (ceRNA) mechanism)Competing endogenous RNA (ceRNA) activity (acts as a "molecular sponge" for miRNAs such as miR-197-3p that would otherwise downregulate PPIA protein expression)Potential involvement in tumor immunity and mRNA metabolism
03
Disease associations
Cancer (specifically, associated with hepatocellular carcinoma and potentially adrenocortical carcinoma, lung adenocarcinoma, and pancreatic adenocarcinoma due to upregulation and correlations with survival outcomes)Tumor progression and prognosis markers in cancer
04
Biomarkers
High PPIAP22 expression (potential prognostic biomarker in hepatocellular carcinoma and possibly in other cancers, reflecting poor survival)
Beyond the preview
Go deeper on Peptidylprolyl isomerase A pseudogene 22 (PPIAP22).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 22 (PPIAP22).